Heterogeneity in metastatic breast cancer 18F-fluoroestradiol uptake: clinically actionable, biologically illuminating?
BF Kurland, S Oesterreich - Journal of Nuclear Medicine, 2018 - Soc Nuclear Med
Metastatic breast cancer from an estrogen receptor (ER)–positive primary tumor is rarely
cured, but patients often live for many years with their disease (1). A wide range of therapy …
cured, but patients often live for many years with their disease (1). A wide range of therapy …
18F-fluoroestradiol tumor uptake is heterogeneous and influenced by site of metastasis in breast cancer patients
HH Nienhuis, M van Kruchten, SG Elias… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Heterogeneity of estrogen receptor (ER) expression in breast cancer is recognized.
However, knowledge about varying expression across metastases and surrounding normal …
However, knowledge about varying expression across metastases and surrounding normal …
The uses of 18F-fluoroestradial (FES) PET with and without 18F-fluorodeoxyglucose (FDG) PET in breast cancer evaluation
955 Objectives: 18 F-Fluoroestradiol (FES) is an estrogen analogue that has been shown to
be a promising ER imaging agent in breast cancer. FES uptake correlates with tumor ER …
be a promising ER imaging agent in breast cancer. FES uptake correlates with tumor ER …
Early results of an NCI-sponsored Phase II study of 18F-fluoroestradiol (FES) PET imaging of metastatic breast cancer (MBC)
329 Objectives FES PET imaging reflects estrogen receptor (ER) density in breast cancer
tumors. Identifying low or absent ER expression through PET imaging may help to select …
tumors. Identifying low or absent ER expression through PET imaging may help to select …
NCI-sponsored phase II study of [18f]fluoroestradiol (FES) as a marker of hormone sensitivity of metastatic breast cancer: Initial results.
DA Mankoff, HM Linden, J Link, BF Kurland… - Journal of Clinical …, 2011 - ascopubs.org
e11104 Background: Molecular imaging of regional ER expression in breast cancer by FES
PET has been shown to indentify patients with low or absent uptake who are unlikely to …
PET has been shown to indentify patients with low or absent uptake who are unlikely to …
18F-Fluoroestradiol PET to predict the response to neoadjuvant treatment of luminal breast cancer
D Groheux - Journal of Nuclear Medicine, 2017 - Soc Nuclear Med
TO THE EDITOR: Chae et al.(1) prospectively investigated the ability of pretreatment 18F-
fluoroestradiol PET/CT to predict the pathologic response to neoadjuvant therapy in …
fluoroestradiol PET/CT to predict the pathologic response to neoadjuvant therapy in …
Can fluorine-18 fluoroestradiol positron emission tomography–computed tomography demonstrate the heterogeneity of breast cancer in vivo?
Z Yang, Y Sun, Y Zhang, J Xue, M Wang, W Shi… - Clinical breast …, 2013 - Elsevier
Aim Our study was to investigate the heterogeneity of estrogen receptor (ER) expression
among tumor sites by using fluorine-18 (18 F) fluoroestradiol (FES) positron-emission …
among tumor sites by using fluorine-18 (18 F) fluoroestradiol (FES) positron-emission …
[PDF][PDF] Positron tomographic assessment of 16α-[18F] fluoro-17β-estradiol uptake in metastatic breast carcinoma
AH McGuire, F Dehdashti, BA Siegel… - Journal of Nuclear …, 1991 - Soc Nuclear Med
MATERIALS AND METHODS The study population consisted of 16 non-pregnant women
(mean age 58.7 yr; range 45-83 yr) with radiographic or clinical evidence of recurrent or …
(mean age 58.7 yr; range 45-83 yr) with radiographic or clinical evidence of recurrent or …
Diagnostic accuracy and safety of 16α-[18F] fluoro-17β-estradiol positron emission tomography/computed tomography for the assessment of estrogen receptor status …
SY Chae, SH Ahn, SB Kim, BH Son, JW Lee, BS Ko… - 2018 - Soc Nuclear Med
487 Objectives: The standard diagnostic workup for recurrent or metastatic breast cancer
includes biopsy and determination of tumor estrogen receptor (ER) status. However, biopsy …
includes biopsy and determination of tumor estrogen receptor (ER) status. However, biopsy …
18F-Fluoroestradiol Whole-Body Imaging
BJ Grabher - Journal of Nuclear Medicine Technology, 2023 - Soc Nuclear Med
Treating and managing metastatic breast cancer can be challenging for breast oncologists
and their patients. Estrogen receptors (ERs) in a patient's primary tumor can be either …
and their patients. Estrogen receptors (ERs) in a patient's primary tumor can be either …